Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pharmacyclics Incorporated ( PCYC) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Pharmacyclics Incorporated fell $3.48 (-3.9%) to $86.62 on average volume. Throughout the day, 592,599 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 638,300 shares. The stock ranged in price between $85.81-$90.47 after having opened the day at $89.71 as compared to the previous trading day's close of $90.10. Other companies within the Drugs industry that declined today were: Affymax ( AFFY), down 64%, Star Scientific ( STSI), down 17.2%, Savient Pharmaceuticals ( SVNT), down 14.8%, and Ventrus Biosciences ( VTUS), down 8.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.34 billion and is part of the health care sector. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 55.9% year to date as of the close of trading on Monday. Currently there are four analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Atossa Genetics ( ATOS), up 34.3%, Pacific Biosciences of California ( PACB), up 15.4%, KYTHERA Biopharmaceuticals ( KYTH), up 13.7%, and NPS Pharmaceuticals ( NPSP), up 9.3%, were all gainers within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015